Document Viewer
Groupon's surprise revenue sends stock to 4-month high
Feb 15

Editors Note Adds details, comparisons to last quarter and year.

CHICAGO (AP) _ Groupon shares jumped more than 20 percent on strong revenue after the company reported earnings for the first time since announcing its acquisition of Living Social in October.

The number of customers in North America rose by 2 percent, half of those coming from Living Social. The Chicago company's billings rose 11 percent compared with the same period last year.

Overall revenue at the online daily deal service was $935 million in the fourth quarter, easily beating Wall Street expectations of $911 million. The company had revenue of $917 million in the same period a year ago.

For the year, the company said it added 5.2 million North American customers, its best performance in four years.

Groupon expects gross profit for 2017 to be between $1.30 billion and $1.35 billion _ an increase of $40 to $90 million from 2016 _ as it implements its exit from 11 countries abroad.

On a per-share basis, the company had a loss of 9 cents, but adjusted for one-time gains and costs, came to 7 cents per share, beating Wall Street expectations by a nickel, according to Zacks Investment Research.

The company reported a loss of $52.6 million in its fourth quarter, which it said were driven by non-operating losses, primarily its investment in Ticket Monster.

For the year, the company reported a loss of $194.6 million, or 34 cents per share, swinging to a loss in the period. Revenue was reported as $3.14 billion, close to last year's $3.12 billion.

The company's shares rose 22 percent, or 85 cents, to $4.63 in midday trading.

Groupon shares had been trading above $5 last fall before sinking about 20 percent on the Living Social acquisition announcement and its third-quarter earnings report.


This story was generated in part by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on GRPN at


Keywords: Groupon, Earnings Report

By The Associated Press, Copyright 2017

Simmons Hanly Conroy files lawsuits against drug companies over opioids marketing

    NEW YORK – Simmons Hanly Conroy, one of the nation’s largest law firms focused on consumer protection and mass tort actions, has filed lawsuits on behalf of New York’s Broome and Erie counties against pharmaceutical companies and physicians over what is being called aggressive and fraudulent marketing of prescription opium-like painkillers (opioids) that has led to a drug epidemic in the counties.
    In complaints filed Feb. 1 in the New York Supreme Court, the counties seek relief including compensatory and punitive damages for the millions of dollars they spend each year to combat the public nuisance created by the drug companies’ deceptive marketing campaign that misrepresents the safety and efficacy of long-term opioid use. The lawsuits follow a similar, ongoing action filed by Simmons Hanly Conroy in August 2016 on behalf of Suffolk County, N.Y.

Click Here for Full Story